Analysis of clinical effect of vertebroplasty combined with zoledronate in preventing postoperative recurrence of vertebral fractures

doi:10.11958/20220262

Abstract

Abstract:

Objective To investigate the effect of zoledronic acid on the recurrence of osteoporotic vertebral compression fracture (OVCF) after vertebroplasty. Methods One hundred and fifty-two patients with OVCF were retrospectively collected. According to postoperative zoledronic acid infusion, patients were divided into the zoledronic acid group (68 cases) and the control group (84 cases). The visual analogue scale (VAS) score and bone mineral density (BMD) T value were recorded before operation and at 3, 6 and 12 months after operation. Serum procollagen type I N-terminal peptide (P1NP) and β-collagen degradation products (β-CTX) were measured by enzyme-linked immunosorbent assay. The patients were followed up for 2 years to record the occurrence of vertebral fracture. Results Compared with the control group, BMD T value was significantly increased, VAS score was decreased, β-CTX and P1NP were decreased at 3, 6 and 12 months after operation in the zoledronic acid group (P<0.05). Two years after operation, the recurrence rate of vertebral fracture was lower in the zoledronic acid group (5/84, 5.95%) than that in the control group (11/68, 16.18%) (χ²=4.171, P<0.05). Conclusion Zoledronic acid can effectively prevent the recurrence of vertebral fracture in patients with OVCF after PVP.

Key words: osteoporosis, fractures, compression, zoledronic acid, vertebroplasty, recurrence

CLC Number:

R553.65

Figures/Tables 5

References 15

[1]	LEWIECKI E M. Intravenous zoledronic acid for the treatment of osteoporosis:the evidence of its therapeutic effect[J]. Core Evid, 2010, 4:13-23. doi:10.2147/ce.s6011.
[2]	SUN Y, MA H, YANG F, et al. Clinical efficacy and safety of zoledronic acid combined with PVP/PKP in the treatment of osteoporotic vertebral compression fracture:a systematic review and Meta-analysis of randomized controlled trials[J]. Biomed Res Int, 2021, 2021:6650358. doi:10.1155/2021/6650358.
[3]	ZHOU T, LIN H, WANG H, et al. Comparative study on the biomechanics between improved PVP and traditional PKP in the treatment of vertebral peripheral wall damage-type OVCF[J]. Exp Ther Med, 2017, 14(1):575-580. doi:10.3892/etm.2017.4542.
[4]	皮海菊, 肖淼生, 尚晖. 经皮椎体后凸成形术治疗陈旧性骨质疏松椎体压缩性骨折疗效观察[J]. 中国临床研究, 2017, 30(1):27-30.
	PI H J, XIAO M S, SHANG H. Observation of curative effect of percutaneous kyphoplasty for treatment of old osteoporotic vertebral compression fractures[J]. Chinese Journal of Clinical Research, 2017, 30(1):27-30. doi:10.13429/j.cnki.cjcr.2017.01.007.
[5]	YU W, XU W, JIANG X, et al. Risk factors for recollapse of the augmented vertebrae after percutaneous vertebral augmentation:a systematic review and meta-analysis[J]. World Neurosurg, 2018, 111:119-129. doi:10.1016/j.wneu.2017.12.019.
[6]	GOLDSTEIN C L, CHUTKAN N B, CHOMA T J, et al. Management of the elderly with vertebral compression fractures[J]. Neurosurgery, 2015, 77(Suppl 4):S33-45. doi:10.1227/NEU.0000000000000947.
[7]	SIRIS E S, ADLER R, BILEZIKIAN J, et al. The clinical diagnosis of osteoporosis:a position statement from the National Bone Health Alliance Working Group[J]. Osteoporos Int, 2014, 25(5):1439-1443. doi:10.1007/s00198-014-2655-z.
[8]	蓝涛, 陈扬, 杨欣建. 椎体成形术后再骨折研究进展[J]. 中国脊柱脊髓杂志, 2015, 25(2):179-182.
	LAN T, CHEN Y, YANG X J. Progress on refracture after vertebroplasty[J]. Chinese Journal of Spinal Cord, 2015, 25(2):179-182. doi:10.3969/j.issn.1004-406X.2015.02.14.
[9]	ZHANG H, XU C, ZHANG T, et al. Does percutaneous vertebroplasty or balloon kyphoplasty for osteoporotic vertebral compression fractures increase the incidence of new vertebral fractures? A Meta-Analysis[J]. Pain Physician, 2017, 20(1):E13-E28.
[10]	刘鹤飞, 吴春根, 田庆华, 等. 椎体压缩性骨折PVP术后再发骨折危险因素的研究进展[J]. 介入放射学杂志, 2017, 26(9):855-858.
	LIU H F, WU C G, TIAN Q H, et al. The risk factors of recurrent fracture in patients having received percutaneous vertebroplasty for vertebral compression fracture:recent progress in research[J]. Journal of Interventional Radiology, 2017, 26(9):855-858. doi:10.3969/j.issn.1008-794X.2017.09.020.
[11]	叶向阳, 汤立新, 程省, 等. 骨密度对骨质疏松性椎体压缩性骨折PKP术后骨折再发风险的评估价值[J]. 中国骨质疏松杂志, 2017, 23(2):154-158.
	YE X Y, TANG L X, CHENG S, et al. Value of bone mineral density on the risk of fracture recurrence after PKP in osteoporotic vertebral compression fractures[J]. Chinese Journal of Osteoporosis, 2017, 23(2):154-158. doi:10.3969/j.issn.1006-7108.2017.02.004.
[12]	REID D M, DEVOGELAER J P, SAAG K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis(HORIZON):a multicentre,double-blind,double-dummy,randomised controlled trial[J]. Lancet, 2009, 373(9671):1253-1263. doi:10.1016/S0140-6736(09)60250-6.
[13]	张强, 李文升, 冯良恩, 等. 唑来膦酸对预防腰椎PVP术后再发骨折的疗效评价[J]. 广州医药, 2021, 52(3):52-55.
	ZHANG Q, LI W S, FENG L E, et al. Effect of zoledronic acid on prevention of recurrent fracture after PVP[J]. Guangzhou Medical Journal, 2021, 52(3):52-55. doi:10.3969/j.issn.1000-8535.2021.03.011.
[14]	常青, 史相钦. PKP结合抗骨质疏松药物治疗骨质疏松性椎体压缩性骨折疗效观察[J]. 中国骨与关节损伤杂志, 2015, 30(5):522-523.
	CHANG Q, SHI X Q. Efficacy of PKP combined with anti-osteoporosis drugs in the treatment of osteoporotic vertebral compression fracture[J]. Chinese Journal of Bone and Joint Injury, 2015, 30(5):522-523.
[15]	LI H M, ZHANG R J, GAO H, et al. New vertebral fractures after osteoporotic vertebral compression fracture between balloon kyphoplasty and nonsurgical treatment PRISMA[J]. Medicine (Baltimore), 2018, 97(40):e12666. doi:10.1097/MD.0000000000012666.

组别	n	性别（男/女）	年龄/岁	BMI/（kg/m²）
对照组	68	24/44	71.3±8.7	23.91±2.68
唑来膦酸组	84	21/63	68.8±8.5	23.61±2.51
χ²或t		1.898	1.784	0.711
组别	骨折部位（胸椎/腰椎）		PMMA/mL	手术时间/min
对照组	16/52		5.25±1.26	43.65±6.32
唑来膦酸组	22/62		5.21±1.25	43.52±5.62
χ²或t	0.141		0.196	0.134

组别	n	性别（男/女）	年龄/岁	BMI/（kg/m²）
对照组	68	24/44	71.3±8.7	23.91±2.68
唑来膦酸组	84	21/63	68.8±8.5	23.61±2.51
χ²或t		1.898	1.784	0.711
组别	骨折部位（胸椎/腰椎）		PMMA/mL	手术时间/min
对照组	16/52		5.25±1.26	43.65±6.32
唑来膦酸组	22/62		5.21±1.25	43.52±5.62
χ²或t	0.141		0.196	0.134

组别	n	术前	术后3个月	术后6个月	术后12 个月
对照组	68	-2.70±0.18	-2.73±0.15	-2.75±0.28	-2.84±0.30
唑来膦酸组	84	-2.73±0.15	-2.31±0.22	-2.03±0.18	-1.86±0.37
t		1.937	13.416^＊＊	19.182^＊＊	17.643^＊＊

组别	n	术前	术后3个月	术后6个月	术后12 个月
对照组	68	-2.70±0.18	-2.73±0.15	-2.75±0.28	-2.84±0.30
唑来膦酸组	84	-2.73±0.15	-2.31±0.22	-2.03±0.18	-1.86±0.37
t		1.937	13.416^＊＊	19.182^＊＊	17.643^＊＊

组别	n	术前	术后3个月	术后6个月	术后12个月
对照组	68	7.74±1.56	3.68±2.10	3.09±1.95	2.89±1.95
唑来膦酸组	84	7.58±1.23	2.92±1.24	2.29±1.14	1.81±0.95
t		0.707	2.774^＊	3.154^＊＊	4.466^＊＊